Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 7, 2013

Waters Introduces Mass Detector for Chromatography Separations

The Waters ACQUITY QDa Detector is a mass detector designed to bring high-quality, mass spectral data to chromatographic separations.

The Waters ACQUITY QDa Detector is a mass detector designed to bring high-quality, mass spectral data to chromatographic separations. The detector, introduced on Oct. 7 by Waters Corp., is now shipping worldwide.

Designed as a component of a chromatographic system, the ACQUITY QDa Detector is compatible with Waters ACQUITY UltraPerformance LC, ACQUITY UltraPerformance Convergence Chromatography, Alliance high performance liquid chromatography and Waters supercritical fluid chromatography and LC-based purification systems.

The system is designed for analytical scientists who need mass spectral data without the complexity of a mass spectrometer. It features automated sample analysis and eliminates sample-specific adjustments for certainty in sample results, from user to user and system to system. The detector generates the high quality mass spectral data expected of a single quadrupole mass spectrometer in a mass detector no bigger than a photodiode array (PDA) detector.

The ACQUITY QDa Detector complements optical detection, such as the PDA detector, by confirming the identity of compounds with mass spectral information; quantifies compounds having no UV response or that are present at levels not detectable and quantifiable by optical detection, the company reports.

The ACQUITY QDa Detector is available for separations systems running Empower 2 and 3 Chromatography Data System software, including enterprise deployment with automated qualification. The ACQUITY QDa Detector is also available now for MassLynx 4.1 Mass Spectrometry Software.

Source: Waters Corp.

 


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.